AbbVie Inc

More Details of AbbVie Inc Company

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Company Info

Company codeABBV

Company nameAbbVie Inc

IPO dateJan 02, 2013

Founded at2012

CEOMr. Robert A. Michael, CPA

Number of employees55000

Security typeOrdinary Share

Fiscal year-endJan 02

Address1 N Waukegan Rd

CityNORTH CHICAGO

Stock exchangeNYSE Consolidated

CountryUnited States of America

Postal code60064

Phone18479327900

Websitehttps://www.abbvie.com/

Company codeABBV

IPO dateJan 02, 2013

Founded at2012

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Richard A. Gonzalez

Executive Chairman of the Board

386.48K

-2.18%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

--

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

--

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

--

Ms. Roxanne S. Austin, CPA

Lead Independent Director

37.26K

--

Dr. Robert J. Alpern, M.D.

Independent Director

34.44K

--

Mr. Frederick H. (Rick) Waddell

Independent Director

27.75K

--

Ms. Melody B. Meyer

Independent Director

15.29K

--

Name

Name/Position

Position

Shareholding

Change

Mr. Richard A. Gonzalez

Executive Chairman of the Board

386.48K

-2.18%

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

-17.22%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

133.43K

--

Mr. Glenn Fletcher Tilton

Independent Director

50.71K

--

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Mr. Edward J. (Ed) Rapp

Independent Director

41.74K

--

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

11.72B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.60%

Hematologic Oncology-IMBRUVICA

3.35B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.83%

Other

23.02B

40.87%

By RegionUSD

Name

Revenue

Proportion

United States

40.78B

72.39%

International

11.51B

20.42%

All other countries

3.03B

5.38%

Germany

1.47B

2.60%

Japan

1.12B

1.99%

Other

-1.57B

-2.79%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Immunology-SKYRIZI

11.72B

20.80%

Immunology-HUMIRA

8.99B

15.96%

Immunology-RINVOQ

5.97B

10.60%

Hematologic Oncology-IMBRUVICA

3.35B

5.94%

Neuroscience-Botox Therapeutic

3.28B

5.83%

Other

23.02B

40.87%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.74%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Global Advisors (US)

4.50%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.65%

Shareholder Statistics

Shareholder

Proportion

The Vanguard Group, Inc.

9.74%

BlackRock Institutional Trust Company, N.A.

5.09%

State Street Global Advisors (US)

4.50%

Geode Capital Management, L.L.C.

2.10%

Capital Research Global Investors

1.92%

Other

76.65%

Type

Shareholder

Proportion

Investment Advisor

33.94%

Investment Advisor/Hedge Fund

29.85%

Research Firm

2.77%

Bank and Trust

2.24%

Pension Fund

2.23%

Sovereign Wealth Fund

1.52%

Insurance Company

0.63%

Hedge Fund

0.51%

Family Office

0.19%

Other

26.12%

Institutional Shareholding

Update time: Thu, Feb 20

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

5158

1.32B

74.37%

+12.52M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

2023Q1

4658

1.27B

71.97%

-18.58M

2022Q4

4628

1.27B

71.69%

-10.55M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

172.31M

9.74%

+1.45M

+0.85%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

90.08M

5.09%

+893.98K

+1.00%

Dec 31, 2024

State Street Global Advisors (US)

79.62M

4.5%

+553.55K

+0.70%

Dec 31, 2024

Geode Capital Management, L.L.C.

37.14M

2.1%

+983.89K

+2.72%

Dec 31, 2024

Capital Research Global Investors

33.98M

1.92%

+778.13K

+2.34%

Dec 31, 2024

JP Morgan Asset Management

33.90M

1.92%

+881.83K

+2.67%

Dec 31, 2024

Capital International Investors

28.53M

1.61%

-8.25M

-22.44%

Dec 31, 2024

Charles Schwab Investment Management, Inc.

27.44M

1.55%

+3.60M

+15.10%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

25.10M

1.42%

+2.62M

+11.64%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

22.68M

1.28%

+844.34K

+3.87%

Dec 31, 2024

Related ETFs

Update time: Sun, Apr 6

Name

Proportion

First Trust Morningstar Dividend Leaders Index Fund

9.82%

First Trust NASDAQ Pharmaceuticals ETF

8.98%

Proshares Ultra Health Care

6.94%

VanEck Pharmaceutical ETF

6.94%

Health Care Select Sector SPDR Fund

6.81%

iShares U.S. Healthcare ETF

6.71%

Goldman Sachs Future Health Care Equity ETF

6.07%

Fidelity MSCI Health Care Index ETF

5.92%

Invesco Pharmaceuticals ETF

5.84%

Themes US Cash Flow Champions ETF

5.7%

First Trust Morningstar Dividend Leaders Index Fund

Proportion9.82%

First Trust NASDAQ Pharmaceuticals ETF

Proportion8.98%

Proshares Ultra Health Care

Proportion6.94%

VanEck Pharmaceutical ETF

Proportion6.94%

Health Care Select Sector SPDR Fund

Proportion6.81%

iShares U.S. Healthcare ETF

Proportion6.71%

Goldman Sachs Future Health Care Equity ETF

Proportion6.07%

Fidelity MSCI Health Care Index ETF

Proportion5.92%

Invesco Pharmaceuticals ETF

Proportion5.84%

Themes US Cash Flow Champions ETF

Proportion5.7%

Dividend

A total of 48.58B USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

186.070USD

AbbVie Inc

186.070

Overview

Company